Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 3/3/2019 |
| Start Date: | March 2011 |
| End Date: | December 2018 |
A Pilot Study to Evaluate the Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Eltrombopag may improve the cell collection available for Autologous Stem Cell
Transplant(ASCT). The overall goal is to determine if adding Eltrombopag to the standard ASCT
will increase the number of blood cells collected and reduce the number of times blood needs
to be collected. This study will also determine the highest dose of Eltrombopag that can be
used without causing serious side effects.
Transplant(ASCT). The overall goal is to determine if adding Eltrombopag to the standard ASCT
will increase the number of blood cells collected and reduce the number of times blood needs
to be collected. This study will also determine the highest dose of Eltrombopag that can be
used without causing serious side effects.
Subjects will receive standard treatment for autologous stem cell transplant. Subjects will
be assigned to receive no Eltrombopag or one of three dose levels of Eltrombopag. Subjects
will receive oral Eltrombopag on days 2-15 of treatment.
be assigned to receive no Eltrombopag or one of three dose levels of Eltrombopag. Subjects
will receive oral Eltrombopag on days 2-15 of treatment.
Inclusion Criteria:
- Multiple myeloma
- Stable or responsive disease after at least 2 cycles of conventional chemotherapy
- Slated to undergo autologous peripheral blood stem cell transplant
- Normal organ and marrow function
Exclusion Criteria:
- Myocardial infarction within 6 months of treatment
- Receiving other study agents
- Pregnant or breastfeeding
- Uncontrolled intercurrent illness
- Evidence of active or recent history of thromboembolic disease
- Previous history of primary platelet disorder or bleeding disorder
- History of a different malignancy unless disease free for at least 5 years
We found this trial at
1
site
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Nancy Berliner, MD
Phone: 617-732-5840
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
